JW Lifescience Corporation (KRX: 234080)

JW Lifescience Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	214,510	206,860	188,931	169,817	183,521	170,221
Other Revenue	-	-	-0	-0	-	-
Revenue	214,510	206,860	188,931	169,817	183,521	170,221
Revenue Growth (YoY)	7.23%	9.49%	11.26%	-7.47%	7.81%	9.66%
Cost of Revenue	160,421	154,507	140,972	120,788	124,243	121,799
Gross Profit	54,090	52,353	47,959	49,029	59,278	48,422
Selling, General & Admin	16,505	15,100	13,358	12,908	13,180	13,833
Research & Development	5,229	5,161	5,737	6,242	5,195	3,583
Other Operating Expenses	266.31	161.56	159.04	162.39	199.85	218.51
Operating Expenses	22,891	21,491	20,870	20,612	19,827	18,673
Operating Income	31,199	30,862	27,089	28,417	39,451	29,749
Interest Expense	-2,286	-2,693	-3,092	-1,281	-2,609	-1,726
Interest & Investment Income	1,183	1,130	1,087	130.36	1,427	34.3
Earnings From Equity Investments	3,218	6,489	-4,921	-4,780	-7,129	0.14
Currency Exchange Gain (Loss)	85.46	-651.41	329.73	-149.04	-150.86	-118.6
Other Non Operating Income (Expenses)	-1,230	-1,251	296.71	-3,772	-8,197	373.21
EBT Excluding Unusual Items	32,169	33,886	20,789	18,565	22,791	28,312
Gain (Loss) on Sale of Assets	4.9	-	-	1.71	-4.14	18.96
Asset Writedown	-165.33	-166.58	-7.42	-279.65	-46.75	-
Other Unusual Items	-	-10.72	-	-	-	-
Pretax Income	32,055	33,708	20,782	18,287	22,740	28,331
Income Tax Expense	5,446	5,564	5,821	5,373	5,440	6,393
Net Income	26,609	28,144	14,961	12,914	17,300	21,938
Net Income to Common	26,609	28,144	14,961	12,914	17,300	21,938
Net Income Growth	28.41%	88.11%	15.86%	-25.36%	-21.14%	38.67%
Shares Outstanding (Basic)	15	15	15	16	16	16
Shares Outstanding (Diluted)	15	15	15	16	16	16
Shares Change (YoY)	-0.03%	-	-0.61%	-1.61%	-	-
EPS (Basic)	1718.41	1817.55	966.21	828.84	1092.55	1385.48
EPS (Diluted)	1718.00	1817.55	966.00	828.84	1092.55	1385.48
EPS Growth	28.42%	88.15%	16.55%	-24.14%	-21.14%	38.67%
Free Cash Flow	16,429	29,421	6,049	11,189	30,824	16,183
Free Cash Flow Per Share	1060.97	1900.03	390.67	718.14	1946.62	1022.02
Dividend Per Share	500.000	500.000	500.000	500.000	500.000	500.000
Gross Margin	25.22%	25.31%	25.38%	28.87%	32.30%	28.45%
Operating Margin	14.54%	14.92%	14.34%	16.73%	21.50%	17.48%
Profit Margin	12.40%	13.61%	7.92%	7.60%	9.43%	12.89%
Free Cash Flow Margin	7.66%	14.22%	3.20%	6.59%	16.80%	9.51%
EBITDA	46,873	46,393	42,045	41,661	51,697	41,375
EBITDA Margin	21.85%	22.43%	22.25%	24.53%	28.17%	24.31%
D&A For EBITDA	15,674	15,531	14,956	13,245	12,246	11,626
EBIT	31,199	30,862	27,089	28,417	39,451	29,749
EBIT Margin	14.54%	14.92%	14.34%	16.73%	21.50%	17.48%
Effective Tax Rate	16.99%	16.51%	28.01%	29.38%	23.92%	22.56%
Advertising Expenses	-	1,731	1,605	1,666	1,039	1,750

Source: S&P Capital IQ. Standard template. Financial Sources.